Metabolic endotoxemia · screening

Metabolic Endotoxemia: What to Measure When Zonulin Cannot

Metabolic endotoxemia is bacterial endotoxin leaking from the gut into the blood at levels that disturb metabolism. Screening it in primary care means measuring the response rather than the exposure: insulin resistance, adipose-driven inflammation and vascular risk.

Barrier failure is measurable and, in one cohort, preceded disease by years. The serum marker patients bring in does not measure it, and the downstream metabolic injury is where screening earns its place.

Metabolic endotoxemia, the passage of bacterial endotoxin from the gut into the circulation at levels that disturb metabolism, is usually filed as a gastroenterology question. Its measurable consequences land in primary care: insulin resistance, adipose inflammation and vascular risk. The accompanying chapter video covers Chapter 4 of The Angry Gut by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Ami Michelle Grimes. For a screening program the book’s case reduces to three propositions: barrier failure is real and measurable, the serum marker patients arrive with does not measure it, and the downstream metabolic injury is where measurement changes management.

The barrier in question is the outer surface of what the book calls the first brain, with the skull holding the second brain, and metaflammation begins where that barrier fails. Dr. Padda was trained to dismiss a zonulin printout and abandoned the reflex; neither the dismissal nor the printout survives the evidence.

The zonulin assay has failed validation twice

Zonulin was characterized as pre-haptoglobin-2. Scheffler and colleagues measured serum zonulin with the most widely used commercial ELISA in 376 people genotyped for haptoglobin. Readings did not follow genotype, the kit returned signal in individuals who cannot synthesize the target, and it did not detect the purified protein; the leading candidate for what it binds is properdin. Ajamian and colleagues tested two further commercial kits and identified the bound material by mass spectrometry as haptoglobin and a complement protein.

Power and colleagues then ran the comparison that matters clinically, serum zonulin against the lactulose-to-mannitol test in first-degree relatives of patients with Crohn’s disease: r2 = 0.004, p < 0.71. In a head-to-head evaluation of six candidate markers in 78 people, only plasma LBP tracked the sugar test in every cohort; plasma zonulin and plasma I-FABP did not.

The originators now describe zonulin as a family of proteins that includes properdin, a position built on a cultured cell monolayer. Whatever the kits detect does rise with obesity, diabetes, and glucose and lipid markers. That makes the result a vague metabolic signal rather than a barrier measurement, and it should not anchor a diagnosis or an elimination diet in the chart.

How is intestinal permeability measured?

Permeability is measured functionally, with oral sugar probes and timed urine collection. Validation in 60 healthy adults on controlled diets established reference recoveries and three practical constraints. Unlabeled mannitol was present in baseline urine in every participant, so the labeled isotope is required. Between-person variation was large, with a median coefficient of variation of 76.5%. And the conventional lactulose-to-mannitol ratio is a weak statistic: in inflammatory bowel disease, labeled mannitol (P = .003) and lactulose (P = .006) each separated patients from volunteers while the ratio did not (P = .237).

None of this is offered by Measura [Cardiometabolic and Autonomic Health Analysis]; it is a referral-level investigation ordered when a gastrointestinal question warrants it.

Done properly, barrier measurement has prognostic weight in at least one cohort. In 1,420 healthy first-degree relatives of patients with Crohn’s disease followed a median 7.8 years, abnormal baseline permeability predicted Crohn’s disease at a hazard ratio of 3.03 (95% CI, 1.64-5.63), and at 1.62 when restricted to tests done more than three years before diagnosis. The counterpoint belongs beside it: relatives from multiplex families carried a 3.65-fold risk without more permeable barriers, and a graded review of eight studies in obesity and metabolic syndrome found very low to low certainty and no clear relationship. The practice position is that the barrier is one road into metabolic disease, and the evidence tier for the metabolic link is mechanism.

How does endotoxin cause insulin resistance?

The human endotoxin challenge is the cleanest mechanistic evidence. In twenty healthy volunteers given 3 ng/kg intravenously, peripheral insulin sensitivity fell 35% at 24 hours while the acute insulin response was unchanged (711 to 744, P = 0.7), and HOMA-IR rose from 1.56 to 2.17. It was a pharmacological bolus that produced fever, not chronic low-grade exposure, and the investigators say so.

The dietary version is subtler and closer to clinic. After a 910-calorie high-fat, high-carbohydrate meal, plasma endotoxin rose 47%, mononuclear-cell TLR4 and SOCS-3 expression rose, and NF-kappaB binding increased 72%, yet plasma CRP and TNF-alpha did not change. A routine inflammatory marker can stay normal while the signaling that produces insulin resistance is active.

Across ten years in 7,169 adults, the top quartile of endotoxin activity carried 52% higher risk of incident diabetes than the bottom; per unit the hazard ratio was 1.004, and activity rose linearly with the number of metabolic syndrome components. In women in The Gambia measured by mass spectrometry, endotoxin was 57% higher with obesity plus diabetes and no different between women with and without obesity, while adipose macrophage markers rose in a clean gradient across the three groups.

The screening insight is that exposure and response diverge. Eighteen healthy men overfed by 760 kcal a day for eight weeks raised postprandial endotoxemia 160%, yet only half of the postprandial arm mounted an inflammatory response. Everyone was exposed; the terrain decided who was injured. Screening the exposure tells you little. Screening the response, insulin resistance and adipose-driven inflammation, tells you who needs management.

Vascular and cognitive signals worth pairing

Endotoxin’s best-documented destination is the arterial wall. In a Finnish cohort of 2,452 adults followed ten years, high endotoxin activity predicted coronary events at a hazard ratio of 1.88; in the Bruneck population, endotoxin above the 90th percentile carried an odds ratio of 2.9 for developing carotid atherosclerosis, concentrated in smokers. Arterial stiffness and endothelial function measure the vessel the mechanism points at, whichever explanation wins.

The second brain is exposed too. In 51 women given high-saturated-fat and high-oleic meals in crossover, higher baseline LBP predicted less consistent post-meal attention (P = 0.04); endotoxin itself was not measured and two-thirds were breast cancer survivors. That is a thin but specific reason to record a cognitive assessment baseline in the same patients, alongside the work described in cognitive assessment and fall prevention.

Who should be tested for metabolic endotoxemia, and what does a finding change?

• Patients presenting with a commercial zonulin result or a self-directed elimination diet. The result is not actionable; the metabolic question behind it is.
• Long-term daily NSAID users, heavy drinkers and patients with periodontal disease. Each carries a measured barrier or endotoxin exposure, and the indication belongs in the problem list.
• Normal-weight patients with features of insulin resistance. The Gambian gradient followed diabetes, not body size, which is where bioimpedance body composition earns its place over BMI.

Food environments built around high-fat, high-sugar meals, over-the-counter anti-inflammatories, and short visits that reward refills over workups all load the same barrier. A finding changes management when it moves a patient from reassurance to a metabolic plan: laboratory panels quantifying insulin resistance, body composition defining the fat and muscle compartments, and lifestyle work prescribed as treatment with its physiological reason documented. Findings that raise a true gastrointestinal question go to gastroenterology for validated permeability testing. Written selection criteria keep that consistent across clinicians.

Standing orders and documentation

Criteria like these belong in standing orders so they run the same way for every eligible patient rather than by memory. Insulin resistance, body composition and vascular findings documented at the annual wellness visit support the measures described in MIPS and quality reporting, and structured results reach the chart through getting results into the record. The patient-facing version, written for someone holding a zonulin printout, is how to test for leaky gut. The liver, first to receive what crosses the barrier, is the subject of MASLD in primary care, and every study cited here is set out with its limits in the Chapter 4 companion.

Frequently asked questions

Should serum zonulin be used to screen for intestinal permeability?

No. Commercial zonulin assays failed validation in two independent laboratories, did not follow haptoglobin genotype, and showed no correlation with a lactulose-to-mannitol test in the same subjects. Whatever they detect tracks obesity and glycemia, so that metabolic signal is better measured directly. The screening logic for cardiometabolic measurement is laid out in clinical rationale.

Is intestinal permeability testing part of the Measura protocol?

No. Timed urine sugar-probe testing with labeled mannitol is a gastroenterology investigation performed elsewhere. Measura measures the downstream terrain: laboratory markers of insulin resistance and inflammation, body composition, vascular function and cognition, with findings returned to the ordering physician. How those measures fit different specialties is described in specialty applications.

What does metabolic endotoxemia change in management?

It reframes insulin resistance in a patient without obesity as a signaling problem worth measuring rather than a weight problem to be waved off. A documented decline in insulin sensitivity, an adverse fat-to-muscle profile or abnormal vascular function moves the patient into an active metabolic plan with repeat measurement. Reading those results in context is covered in interpreting the report.

How do these findings fit the annual wellness visit?

The wellness visit already structures risk assessment, cognitive screening and a written prevention plan. Metabolic, body composition and vascular findings slot into that plan as measured risk factors with a repeat interval, which makes change over time documentable rather than anecdotal. Practical placement within the visit is described in annual wellness visit integration.

How is metabolic endotoxemia treated?

By measuring and managing the response rather than the exposure. A finding moves the patient from reassurance to a metabolic plan: laboratory panels that quantify insulin resistance, body composition that defines the fat and muscle compartments, and lifestyle work prescribed as treatment with its physiological reason documented, followed by repeat measurement. Findings that raise a true gastrointestinal question go to gastroenterology for validated permeability testing.

References

• Scheffler, L., Crane, A., Heyne, H., Tonjes, A., Schleinitz, D., Ihling, C. H., Stumvoll, M., Freire, R., Fiorentino, M., Fasano, A., Kovacs, P., & Heiker, J. T. (2018). Widely used commercial ELISA does not detect precursor of haptoglobin2, but recognizes properdin as a potential second member of the zonulin family. Frontiers in Endocrinology, 9, 22. https://doi.org/10.3389/fendo.2018.00022
• Power, N., Turpin, W., Espin-Garcia, O., Smith, M. I., CCC GEM Project Research Consortium, & Croitoru, K. (2021). Serum zonulin measured by commercial kit fails to correlate with physiologic measures of altered gut permeability in first degree relatives of Crohn’s disease patients. Frontiers in Physiology, 12, 645303. https://doi.org/10.3389/fphys.2021.645303
• Seethaler, B., Basrai, M., Neyrinck, A. M., Nazare, J. A., Walter, J., Delzenne, N. M., & Bischoff, S. C. (2021). Biomarkers for assessment of intestinal permeability in clinical practice. American Journal of Physiology. Gastrointestinal and Liver Physiology, 321(1), G11–G17. https://doi.org/10.1152/ajpgi.00113.2021
• Khoshbin, K., Khanna, L., Maselli, D., Atieh, J., Breen-Lyles, M., Arndt, K., Rhoten, D., Dyer, R. B., Singh, R. J., Nayar, S., Bjerkness, S., Harmsen, W. S., Busciglio, I., & Camilleri, M. (2021). Development and validation of test for “leaky gut” small intestinal and colonic permeability using sugars in healthy adults. Gastroenterology, 161(2), 463–475.e13. https://doi.org/10.1053/j.gastro.2021.04.020
• Turpin, W., Lee, S.-H., Raygoza Garay, J. A., Madsen, K. L., Meddings, J. B., Bedrani, L., Power, N., Espin-Garcia, O., Xu, W., Smith, M. I., Griffiths, A. M., Moayyedi, P., Turner, D., Seidman, E. G., Steinhart, A. H., Marshall, J. K., Jacobson, K., Mack, D., Huynh, H., … Croitoru, K. (2020). Increased intestinal permeability is associated with later development of Crohn’s disease. Gastroenterology, 159(6), 2092–2100.e5. https://doi.org/10.1053/j.gastro.2020.08.005
• Bona, M. D., Torres, C. H. de M., Lima, S. C. V. C., Morais, A. H. de A., Lima, A. Â. M., & Maciel, B. L. L. (2022). Intestinal barrier permeability in obese individuals with or without metabolic syndrome: a systematic review. Nutrients, 14(17), 3649. https://doi.org/10.3390/nu14173649
• Mehta, N. N., McGillicuddy, F. C., Anderson, P. D., Hinkle, C. C., Shah, R., Pruscino, L., Tabita-Martinez, J., Sellers, K. F., Rickels, M. R., & Reilly, M. P. (2010). Experimental endotoxemia induces adipose inflammation and insulin resistance in humans. Diabetes, 59(1), 172–181. https://doi.org/10.2337/db09-0367
• Ghanim, H., Abuaysheh, S., Sia, C. L., Korzeniewski, K., Chaudhuri, A., Fernandez-Real, J. M., & Dandona, P. (2009). Increase in plasma endotoxin concentrations and the expression of Toll-like receptors and suppressor of cytokine signaling-3 in mononuclear cells after a high-fat, high-carbohydrate meal: Implications for insulin resistance. Diabetes Care, 32(12), 2281–2287. https://doi.org/10.2337/dc09-0979
• Laugerette, F., Alligier, M., Bastard, J.-P., Drai, J., Chanséaume, E., Lambert-Porcheron, S., Laville, M., Morio, B., Vidal, H., & Michalski, M.-C. (2014). Overfeeding increases postprandial endotoxemia in men: Inflammatory outcome may depend on LPS transporters LBP and sCD14. Molecular Nutrition & Food Research, 58(7), 1513–1518. https://doi.org/10.1002/mnfr.201400044
• Madison, A. A., Belury, M. A., Andridge, R., Shrout, M. R., Renna, M. E., Malarkey, W. B., Bailey, M. T., & Kiecolt-Glaser, J. K. (2020). Afternoon distraction: A high-saturated-fat meal and endotoxemia impact postmeal attention in a randomized crossover trial. The American Journal of Clinical Nutrition, 111(6), 1150–1158. https://doi.org/10.1093/ajcn/nqaa085

Related reading

• The LF/HF Ratio Is Not Vagal Tone: Autonomic Testing in Gut Patients
• MASLD in Primary Care: Screening When Liver Enzymes Look Normal
• Laboratory Panels

Medically reviewed by Dr. Gurpreet Singh Padda, MD, MBA, MHP, medical director of Measura. Last reviewed September 12, 2026.